BioCentury
ARTICLE | Clinical News

Synta halting ganetespib study after futility analysis

October 22, 2015 1:00 AM UTC

Synta Pharmaceuticals Corp. (NASDAQ:SNTA) sank $1.30 (64%) to $0.74 after it said it will terminate the Phase III GALAXY-2 trial of ganetespib ( STA-9090) to treat advanced non-small cell lung cancer (NSCLC). Synta said that after an interim futility analysis, an IDMC determined that the addition of ganetespib to docetaxel was unlikely to significantly improve overall survival (OS), the study's primary endpoint.

Enrollment will continue in four other investigator-sponsored clinical studies of the small molecule heat shock protein 90 ( Hsp90) inhibitor to treat ovarian cancer, acute myelogenous leukemia (AML), high-risk myelodysplastic syndromes (MDS) and breast cancer. President and CEO Chen Schor said on a conference call Wednesday that Synta expects the first data from the studies next year. ...